UNLABELLED: ACKGROUND:: Arteriovenous malformations cause significant morbidity, primarily because they expand over time and recur after treatment. The authors hypothesized that neovascularization might contribute to arteriovenous malformation progression. METHODS: Arteriovenous malformation tissue was collected prospectively from 12 patients after resection. Schobinger stage was determined by clinical history. Neovascularization in stage II lesions (n=7) was compared with stage III arteriovenous malformations (n=5) that had progressed. Specimens were analyzed using immunohistochemistry for CD31, Ki67, and CD34/CD133. Quantitative real-time reverse-transcriptase polymerase chain reaction was used to determine mRNA expression of factors that recruit endothelial progenitor cells: vascular endothelial growth factor (VEGF), stromal cell-derived factor-1α (SDF-1α), and hypoxia-inducible factor-1α (HIF-1α). VEGF receptors (VEGFR1, VEGFR2, neuropilin 1, and neuropilin 2) also were quantified using quantitative real-time reverse-transcriptase polymerase chain reaction. RESULTS: Stage III arteriovenous malformations showed greater microvessel density (5.8 percent) than stage II lesions (1.3 percent) (p=0.004); no difference in proliferating endothelial cells was noted (p=0.67). CD133CD34 endothelial progenitor cells were elevated in stage III (0.53 percent) compared with stage II arteriovenous malformations (0.25 percent) (p=0.03). HIF-1α and SDF-1α were increased 7.6- and 7.9-fold in stage III compared with stage II lesions (1.7-fold and 3.3-fold), respectively (p=0.02). Neuropilin 1 and neuropilin 2 expression was greater in stage III (5.8-fold and 4.6-fold) than stage II arteriovenous malformations (3.0-fold and 2.4-fold) (p=0.03). CONCLUSIONS: Higher-staged arteriovenous malformations exhibit increased expression of endothelial progenitor cells and factors that stimulate their recruitment. Neovascularization by vasculogenesis may be involved in progression of arteriovenous malformation.
UNLABELLED: ACKGROUND:: Arteriovenous malformations cause significant morbidity, primarily because they expand over time and recur after treatment. The authors hypothesized that neovascularization might contribute to arteriovenous malformation progression. METHODS:Arteriovenous malformation tissue was collected prospectively from 12 patients after resection. Schobinger stage was determined by clinical history. Neovascularization in stage II lesions (n=7) was compared with stage III arteriovenous malformations (n=5) that had progressed. Specimens were analyzed using immunohistochemistry for CD31, Ki67, and CD34/CD133. Quantitative real-time reverse-transcriptase polymerase chain reaction was used to determine mRNA expression of factors that recruit endothelial progenitor cells: vascular endothelial growth factor (VEGF), stromal cell-derived factor-1α (SDF-1α), and hypoxia-inducible factor-1α (HIF-1α). VEGF receptors (VEGFR1, VEGFR2, neuropilin 1, and neuropilin 2) also were quantified using quantitative real-time reverse-transcriptase polymerase chain reaction. RESULTS: Stage III arteriovenous malformations showed greater microvessel density (5.8 percent) than stage II lesions (1.3 percent) (p=0.004); no difference in proliferating endothelial cells was noted (p=0.67). CD133CD34 endothelial progenitor cells were elevated in stage III (0.53 percent) compared with stage II arteriovenous malformations (0.25 percent) (p=0.03). HIF-1α and SDF-1α were increased 7.6- and 7.9-fold in stage III compared with stage II lesions (1.7-fold and 3.3-fold), respectively (p=0.02). Neuropilin 1 and neuropilin 2 expression was greater in stage III (5.8-fold and 4.6-fold) than stage II arteriovenous malformations (3.0-fold and 2.4-fold) (p=0.03). CONCLUSIONS: Higher-staged arteriovenous malformations exhibit increased expression of endothelial progenitor cells and factors that stimulate their recruitment. Neovascularization by vasculogenesis may be involved in progression of arteriovenous malformation.
Authors: Brock A Peters; Luis A Diaz; Kornelia Polyak; Leslie Meszler; Kathy Romans; Eva C Guinan; Joseph H Antin; David Myerson; Stanley R Hamilton; Bert Vogelstein; Kenneth W Kinzler; Christoph Lengauer Journal: Nat Med Date: 2005-02-20 Impact factor: 53.440
Authors: Yuval Shaked; Francesco Bertolini; Shan Man; Michael S Rogers; Dave Cervi; Thomas Foutz; Kimberley Rawn; Daniel Voskas; Daniel J Dumont; Yaacov Ben-David; Jack Lawler; Jack Henkin; Jim Huber; Daniel J Hicklin; Robert J D'Amato; Robert S Kerbel Journal: Cancer Cell Date: 2005-01 Impact factor: 31.743
Authors: Akira Orimo; Piyush B Gupta; Dennis C Sgroi; Fernando Arenzana-Seisdedos; Thierry Delaunay; Rizwan Naeem; Vincent J Carey; Andrea L Richardson; Robert A Weinberg Journal: Cell Date: 2005-05-06 Impact factor: 41.582
Authors: T Asahara; H Masuda; T Takahashi; C Kalka; C Pastore; M Silver; M Kearne; M Magner; J M Isner Journal: Circ Res Date: 1999-08-06 Impact factor: 17.367
Authors: S M Hyder; J C Huang; Z Nawaz; H Boettger-Tong; S Mäkelä; C Chiappetta; G M Stancel Journal: Environ Health Perspect Date: 2000-10 Impact factor: 9.031
Authors: Mark E Kleinman; Oren M Tepper; Jennifer M Capla; Kirit A Bhatt; Daniel J Ceradini; Robert D Galiano; Francine Blei; Jamie P Levine; Geoffrey C Gurtner Journal: Lymphat Res Biol Date: 2003 Impact factor: 2.589
Authors: A A Kocher; M D Schuster; M J Szabolcs; S Takuma; D Burkhoff; J Wang; S Homma; N M Edwards; S Itescu Journal: Nat Med Date: 2001-04 Impact factor: 53.440
Authors: Oren M Tepper; Jennifer M Capla; Robert D Galiano; Daniel J Ceradini; Matthew J Callaghan; Mark E Kleinman; Geoffrey C Gurtner Journal: Blood Date: 2004-09-23 Impact factor: 22.113
Authors: Steven R Tandberg; Thèrése Bocklage; Mary R Bartlett; Leslie A Morrison; Jeffrey Nelson; Blaine L Hart Journal: AJR Am J Roentgenol Date: 2019-12-11 Impact factor: 3.959
Authors: Daphne Lobeek; Frédérique C M Bouwman; Erik H J G Aarntzen; Janneke D M Molkenboer-Kuenen; Uta E Flucke; Ha-Long Nguyen; Miikka Vikkula; Laurence M Boon; Willemijn Klein; Peter Laverman; Wim J G Oyen; Otto C Boerman; Samantha Y A Terry; Leo J Schultze Kool; Mark Rijpkema Journal: J Nucl Med Date: 2019-09-13 Impact factor: 10.057
Authors: Claire S Luke Krishnan; Helen D Brasch; Josie Patel; Nicholas Bockett; Erin Paterson; Paul F Davis; Swee T Tan Journal: Front Surg Date: 2021-03-19
Authors: Amalia Mulia Utami; Siham Azahaf; Onno J de Boer; Chantal M A M van der Horst; Lorine B Meijer-Jorna; Allard C van der Wal Journal: J Clin Transl Res Date: 2021-07-30